Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.

Abstract excerpt

Bladder cancer is a heterogeneous malignancy and is responsible for approximately 3.2% of new diagnoses of cancer per year (Sung et al., 2021). Fibroblast Growth Factor Receptors (FGFRs) have recently emerged as a novel therapeutic target in cancer. In particular, FGFR3 genomic alterations are potent oncogenic drivers in bladder cancer and represent predictive biomarkers of response to FGFR inhibitors. Indeed,...

Topics

Join the communities discussing this publication.

• Forecasting
• Genomics
• Mutation
• Oncogenes
• Receptor, Fibroblast Growth Factor, Type 3